Excuse me, everyone. Thank you for standing by. We apologize; we did experience some technical difficulties. We will now begin your conference. Please go ahead. Good morning, everyone. Welcome to our Q4 2022 Earnings and 2023 Guidance Call. With us today is our Executive Chairman, Robert Coury; CEO, Michael Goettler; Incoming CEO, Scott Smith; President, Rajiv Malik; and CFO, Sanjeev Narula. During today's call, we will be making forward-looking statements on a number of matters, including our financial guidance for 2023 and various strategic initiatives. These forward-looking statements are subject to risks and uncertainties that could cause future results or events to differ materially from today's projections. Please refer to today's slide presentation and our SEC filings for a full explanation of those risks and uncertainties and the limits applicable to forward-looking statements. We will be referring to certain actual and projected non-GAAP financial measures to supplement investors' understanding and assessment of our financial performance. Reconciliations of those non-GAAP measures to the most directly comparable GAAP measures are available on our website and in the appendix of today's slide presentation. An archived copy of today's presentation and other earnings materials will be available on our website at investor.viatris.com following the conclusion of today's call. With that, let me welcome Robert Coury.

Good morning. When I spoke with you on November 7th, I shared my excitement for all that I saw ahead for Viatris as we begin to approach the end of Phase I of our strategic plan, which, as you know, has been our setup phase. And now as we prepare to enter Phase II beginning in 2024, I am pleased to report with our eighth consecutive successful quarter of execution behind us, the rebasing of our business model is well-underway. And though we are not giving guidance for 2024, I am even more confident today that we will not only generate a minimum of $2.3 billion of free cash flows, excluding transaction costs and taxes, but now also see the potential for accelerated top line growth from 2023 to 2024 as well. This is on top of the expected top-line growth you saw in this morning's press release between 2022 and 2023 after excluding the full year impact of the biosimilars business in 2022. Now turning to the other press release you saw this morning. The Board of Directors has appointed Scott Smith as Viatris' new Chief Executive Officer, effective April 1st. Scott will lead the company and the execution of our previously and now Phase II strategy. Scott has been a member of the Viatris' Board since December of 2022 and is a deeply knowledgeable senior global biotechnology pharmaceutical executive with over 35 years of experience, including as a former President and Chief Operating Officer of Celgene Corporation, where he built and oversaw the clinical development, registration, launch and global commercial success of the blockbuster drug, Otezla. Most recently, Scott has served as the President of BioAtla, a publicly traded global biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics. The Board views Scott as a seasoned builder who possesses vast global commercial and pharmaceutical expertise and a proven ability to build, grow and manage large complex organizations. We see his strong commercial and strategic expertise being complemented by his experience in organically building product franchises and executing business development and partnering activities. He also has substantial experience in the development of regulatory and clinical strategies that bring products to market. I personally have been very impressed with Scott's overall approach to leadership, his deep industry knowledge and forward-looking business mindset. With our foundation now firmly in place and as we enter into Phase II of our strategic plan, the Board truly believes that Scott is well-positioned for success as he leads the growth of Viatris in the years ahead. We are excited to welcome Scott and believe that he is absolutely the right choice to lead the company into the next phase of our journey. I'd now like to turn the call over to Scott to say a few words himself. Scott?

Thank you, Robert, and good morning to everybody on the call. It's an incredibly exciting time to become Viatris' CEO. I watched closely in November as the company laid out the next important steps in its well-crafted strategic plan, including its commitment to its future capital allocation priorities, which I totally support. Since then and particularly after joining the Board and seeing their incredible level of engagement, I've been extremely impressed by everyone that I've met during this process and have also been inspired by all that has been accomplished in such a short period of time. I strongly identify with Viatris' culture, which, when combined with the company's strategic forward-looking mindset, makes it a natural fit for me. Just as importantly, I'm also motivated by the company's strong financial profile and financial flexibility, which has one of the strongest balance sheets in the sector. I can see many additional opportunities and options for Viatris to accelerate its growth in the coming years. I believe that my franchise building, business development and recent biotech experiences, coupled with the great platform we have to work from can accelerate Viatris' momentum and help deliver on its full value and potential. I would like to thank Robert and the Board for this amazing opportunity and look forward to collaborating with Michael during this transition. I am very excited about the prospect of working with the Board, Rajiv Malik, Sanjeev Narula, and the entire management team on the execution ahead. And lastly, to the company's 37,000 employees, I am honored to have the opportunity to serve each of you and look forward to working with all of you in the near future as we continue to deliver on Viatris' mission to empower people worldwide to live healthier at every stage of life.

Thank you, Scott. The Board and I very much look forward to supporting Scott during the execution of our Phase II strategy, while continuing to remain focused on identifying additional opportunities to further unlock value for our shareholders. Also, as Scott mentioned, Michael will be working closely with him to support a smooth transition and will then step down as CEO and as a member of the Board of Directors on April 1 of this year. I and the Board would like to personally thank Michael for his service and his dedication during this critical time of the creation of Viatris and the establishment of the ongoing execution of our Phase I strategy. We wish him nothing but the best as he moves forward. With that said, I do look forward to answering your questions in the Q&A session. But for now, I'd like to turn the call over to Michael, so he can add a few comments and then also lead the walk-through of our 2022 fourth quarter and full year earnings. Michael?

Thank you, Robert. We began this journey three and a half years ago, when we first made plans to embark on an unprecedented endeavor to combine Mylan and Upjohn to create a company that would span the divide between generic and branded medicines to more fully address patients' expectations and needs around the world. It has been my sincere honor to serve as Viatris' first CEO for the past two years. The opportunity to create a new kind of global health care company has been an experience that I will never forget. I want to thank Robert, the entire Viatris Board of Directors, Rajiv, Sanjeev, my leadership team, but most especially all of Viatris' colleagues around the world whose tireless efforts laid the foundation for what I believe to be a truly bright future. As Viatris now embarks on Phase II of its strategic plan, this is now a natural time for a transition. I'm pleased to welcome Scott into Viatris, and I'm looking forward to supporting him during this transition as he is now well positioned to continue to build on the company's momentum. And now, as usual, here are some highlights for 2022. Quarter four was another strong quarter, in line with our expectations, taking into account the Biocon transaction and IPR&D accounting. For Viatris, this is the eighth consecutive quarter of strong operational performance, closing out another strong year. In 2022, we delivered total revenue of approximately US$16.3 billion, adjusted EBITDA of approximately US$5.8 billion and free cash flow of approximately $2.5 billion on a reported basis, at approximately $2.8 billion after adjusting for the transaction costs and taxes associated with the Biocon transition. This strong performance has not only enabled us to continue to deliver on our Phase 1 commitments, but has also built a solid foundation, setting our company up for 2024 and beyond. Our integration plans have captured approximately $750 million in synergies to date, and we're well on track to capture at least $1 billion of cost synergies by the end of Phase 1, and we've exited substantially all the transitional services agreements with Pfizer. As of the end of 2022, we've paid down approximately $3.3 billion in debt for the year-end and approximately $5.4 billion since the beginning of 2021. We continue to exercise financial discipline, maintaining our investment-grade rating, and continuing to reduce our gross leverage towards our long-term target of three times. We're returning capital to shareholders. Our Board of Directors just approved a 2023 dividend policy of $0.48 per share and has declared a first quarter dividend of $0.12 per share. Cumulatively, since the formation of the address, we've already returned nearly $1 billion to shareholders through dividend payments alone. In January and February of this year, we've executed $250 million of our $1 billion share repurchase authorization. Now combined with the projected annual dividend, this represents an increase to date of more than 40% in returns to shareholders over 2022 or put another way, 33% of the midpoint of our free cash flow guidance for 2023. In addition to that, we're continuing to execute on our plans to reshape our company for the future. In November, we completed our transaction with Biocon Biologics to create what we expect to be a unique, fully integrated global biosimilars leader. As we provide transitional services to Biocon, we're deeply committed to doing our power to help Biocon Biologics succeed. In January, we completed the acquisitions of Oyster Point Pharma and Famy Life Sciences to establish our new Viatris Eye Care division. As we said, we anticipate the combined assets of these acquisitions to add to the top line immediately and grow strong double digits from there, reaching at least $1 billion in sales by 2028. Coupled with the strength of our organic pipeline, especially our complex injectables and novel product franchises, both of which also have the potential to reach $1 billion in peak net sales each by 2028. This kind of business transaction is a very important component of our strategy. And finally, we remain on track to execute our planned and announced divestitures. Today, we'll also be sharing the 2023 full year guidance ranges for total revenue, EBITDA and free cash flow, which Sanjeev will give more details on in a moment. Let me summarize. By being laser-focused on our Phase 1 priorities, integrating the two organizations, generating $1 billion in cost synergies, deleveraging the balance sheet and strengthening the balance sheet, paying down at least $6.5 billion in debt, reducing our gross leverage towards our long-term target of three times, maintaining our investment-grade credit rating, returning capital to shareholders through quarterly dividends and share repurchase programs, and reshaping the company through key divestitures and acquisitions, we are successfully stabilizing the business. This is why, although we're not giving guidance beyond 2023, we're confident in our expectation that 2024 will begin a period of renewed growth for Viatris and generate at least $2.3 billion in free cash flows per year, excluding transaction costs and taxes, of which we intend to earmark approximately 50% annually to be returned to shareholders in the form of dividends or share repurchases. And now for one final time, let me turn it over to Rajiv and Sanjeev to share more details. Rajiv?

Thanks, Michael, and good morning, everyone. 2022 was another solid year of business execution and performance. We met our stated commitments, including delivering the pipeline, integrating and capturing synergies and most importantly, stabilizing the base business. We are really excited about how we see 2023 shaping up, and nothing has changed from what we shared with you on November 7 as we prepare for 2024. Our path to return to growth in Phase 2 is clear and now it’s about continued execution, which is what we do best. One of the key drivers behind the stability of our business is the understanding and effective management of our established brands. This was further evidenced by the better than expected performance of this category in 2022, driven by year-over-year growth from brands like Creon, Lipitor, Celebrex, Dymista, and Yupelri while Norvasc, Amitiza, and Effexor held their ground. We expect this stabilization to continue into 2023 and beyond. Let me now turn to the commercial segments and our expectations for this year. I will be making certain comparisons to 2022 results on a constant currency basis, which excludes the negative impact of foreign exchange, as well as excluding the biosimilars business from 2022. Our 2023 business is on a growth path. We expect to deliver approximately $500 million in new launches, plus $56 million in revenue from Tyrvaya, which more than offsets a 2.9% erosion of our base business. As Robert mentioned in his prepared remarks, while we are not giving guidance beyond 2023, we see the potential for accelerated top line growth as we go into 2024 and beyond. Developed Markets grew by 1% in 2022 on the strength of European growth, offsetting the decline in North America. For 2023, we expect this segment to remain flattish. Europe grew by 4%, primarily driven by the stability of our branded business, new launches, and a strong performance from countries like France and Italy. In 2023, we believe we are well positioned to further grow this region by 3%, led by brands like Creon, Influvac, Lipitor, and our thrombosis portfolio. In North America, despite the solid performance of Yupelri, the business declined by 4% as we navigated the competitive headwinds on key products like Wixela and loss of exclusivity on Miacalcin and Perforomist. We project Yupelri to continue to have strong double-digit growth in 2023, which will help offset the continued competitive pressures on certain key products. These market dynamics will be the primary reasons for our expectation of an approximate 3% decline in 2023. That said, we are excited and look forward to bringing several new products, including generic Symbicort to market this year. Greater China again performed strongly and grew by 3% year-over-year, despite COVID lockdowns in this region. Our hospital business performed relatively better than retail. We believe China has significantly improved the cost efficiency of the medical reimbursement funds, while achieving their goals of providing broader coverage of health care to its population through the successful implementation of VBP and other policies. At the same time, the market has evolved towards publicly reimbursed channels and private paid channels. We have made significant progress in adapting our business model to the evolving market dynamics while focusing on value-added activities to help patients manage their chronic disease states more effectively. These investments are helping us expand the private pay market and also leverage our brand equity in this channel. Keeping in mind the evolving policy framework, we have modeled a small year-over-year decline for 2023. Emerging markets performed in line with expectations and benefited from a solid performance of the overall branded business, led by markets such as the Middle East, Turkey, and Korea. Going into 2023, we are projecting this segment to grow by 4% year-over-year, primarily driven by our branded business. Our Gen segment performed in line with our expectations while continuing to be impacted by the competitive driven price regulations in this region. While our brand Creon grew both in volume and value, our other two key brands, Amitiza and Effexor, showed solid volume growth in 2022. We anticipate strong volume growth to continue for our key brands for 2023. Now let me turn to our newly formed Eye Care division. We are pleased with the tailwinds that we expect with Tyrvaya in 2023. Since the beginning of this year, Medicare Part D coverage has grown from 2% to 32.5% of covered lives. We also launched a 90-day script program, and we are already seeing an uptick in the total prescriptions midway through this high deductible period of the year. We are significantly investing in the business and intend to launch a direct-to-consumer campaign in the fourth quarter of this year that is anticipated to start delivering results in early 2024. Switching to our deep eye care pipeline, our NDA review for reversal of mydriasis program was accepted and has been granted a PDUFA date of September 28 of this year. We have made the decision to terminate our Stage 1 Neurotrophic Keratopathy program because it failed to meet the primary endpoint in the Phase II OLYMPIA study. We have started enrollment in the first pivotal Phase III trial for presbyopia and are also on track to initiate the first Phase III study for the treatment of blepharitis in 2023. With the positive momentum of Tyrvaya and continued progress in our pipeline, we remain confident that our Eye Care division will deliver $1 billion in net sales by 2028. 2022 was a very productive year from a science perspective. We are very pleased with the progress of our complex injectable pipeline. Currently, we have 10 ANDAs under review with the FDA and have secured several first-to-market generic product opportunities such as Sandostatin LAR, Ozempic, Wegovy, and Abilify Maintena. We expect to file a number of complex injectables in 2023, including MR-117 for the treatment of breast cancer, MR-150 indicated for use in iron deficient anemia, and MR-151 for treatment of certain bleeding disorders. Our novel and complex product programs have also progressed well in 2022. As you are aware, our partner, Mapi, has successfully completed the Phase III trial for our Glatiramer Once Monthly, and we are on track to submit this NDA to the FDA by April. We have also initiated a Phase III trial for expanding the indication of Effexor ER in Japan and have made good progress in the recruitment of subjects into our Xulane Low Dose clinical program. Looking ahead into 2023, we believe we are well positioned to initiate a Phase III trial for our meloxicam rapid onset of action dosage form, which we believe has opioid-sparing attributes. We also remain on track to initiate our clinical program for our biosimilar to Botox later this year. For our core and complex generics, we made over 100 additional submissions globally in 2022, and we expect to see this trend continue through 2023. Our program for complex generic MR-153 indicated for treatment of type 2 diabetes and MR-154 indicated for the treatment of SMA are well on track. For China, products were filed with the FDA in 2022, including generic Symbicort. We plan to submit an additional 10 products this year in China. Our operations had yet another year of solid performance, delivering high customer service levels, and we see this strength continuing throughout 2023. From an integration point of view, we were able to exit substantially all the transition services with Pfizer in 2022 and are well on our path to achieve $1 billion in cost synergies by the end of this year. Before I conclude, I would like to thank our colleagues for their hard work and commitment that delivered another year of strong performance. With that, I will now hand the call over to Sanjeev.

Thank you, Rajiv and good morning, everyone. Let me start with what you heard from Robert, in particular as it relates to 2024. We continue to feel confident about the starting point for Phase II as communicated in November of last year, and nothing has changed from then to now. As mentioned, although we are not giving guidance beyond 2023, we expect to have at least $2.3 billion in free cash flow from the underlying business in 2024 before any divestment costs and taxes. This reflects the expected cash flow generation after removing the planned divestiture. 2022 was another strong year for the company, enabling us to deliver on our Phase I commitment while further investing in our business. We're taking bold steps in reshaping the company and remain confident in our strategy to return to growth in Phase II. Moving to slide 26. We finished the year on a strong note across total revenue, adjusted EBITDA, and free cash flow, and results were in line with our expectations. Recall that our previous guidance included full year contributions from the biosimilar business. As a result, because of the Biocon transaction closing in late November, we're adjusting our guidance down by approximately $86 million in total revenue, $31 million in adjusted EBITDA, and $20 million in free cash flow relating to the exclusion of results since closing. Also impacting adjusted EBITDA and free cash flow was $36 million of acquired IPR&D, which was not included in the guidance. Free cash flow was also impacted by $254 million of transaction costs and taxes related to the Biocon transaction. Excluding this impact, free cash flow would have been $2.8 billion on a full year basis. Now, turning to slide 27. Revenue was impacted by foreign exchange, given our significant international operations. Excluding this impact, we're encouraged by the operational stability and diversification of our global portfolio. As mentioned on the third-quarter call, we anticipated adjusted gross margin to moderate in Q4 due to continued inflationary headwinds and product mix. On a full-year basis, adjusted gross margin came in at the high end of our expectation at 58.9%, driven by strong brand performance. Adjusted SG&A and adjusted R&D came in line with our expectations and included certain investments we made in Q4 to support our 2023 plan. We had a very strong year of cash flow generation, reflecting our underlying operational performance and continued organizational priority on cash optimization initiatives. As mentioned before, free cash flow in the fourth quarter was impacted by the Biocon transaction. Excluding this would have been $243 million in Q4 2022. Slide 28 illustrates the uses of the upfront cash proceeds received upon the closing of the Biocon transaction. It is important to note that the gross proceeds of approximately $2 billion are included in the cash flow from investing activities. While the related tax and transaction costs are included as negative cash flows from the operating activities. The net proceeds serve to accelerate debt pay down, fund the eye care acquisition, and execute on share repurchase in Q1 2023. Slide 29 illustrates the continued prioritization of debt pay down, which has resulted in a total paydown of approximately $5.4 billion over the last eight quarters. As a result, and irrespective of divestiture proceeds, we expect to meet our commitment of paying down at least $6.5 billion during Phase I. We exited 2022 with a gross leverage of approximately 3.2 times. These deliberate actions taken by the company reinforce our commitment to the investment-grade rating. Another priority is returning capital to our shareholders, which included approximately $580 million in dividends in 2022 and more than $980 million since the beginning of 2021. Slides 31 and 32 speak to the assumptions and guidance for 2023, which we expect to be a bridge year to get to our starting point in 2024. In 2023, we expect continued strengthening of our financial profile, which includes our expectation that total revenue will grow versus 2022, excluding the contribution of biosimilar. Investment into the Eye Care Division and our strong pipeline for future growth, another strong year of expected free cash flow generation, and our capital allocation framework, which includes debt pay down and significantly enhanced capital return to our shareholders. As previously mentioned, the timing of planned divestiture may create fluctuations in our future reported results. The guidance we presented today includes the anticipated full year performance of businesses that we expect to divest. Similar to the Biocon transaction, we will provide as much transparency as possible on the expected impact on our guidance and results as and when these transactions are announced. Regarding key metrics, we expect slight moderation in our gross margin relative to 2022 levels. This includes the expected pricing impact on key products, base business erosion, and the continued inflation impact. With respect to acquired IPR&D, we do not include any amount in our guidance related to unsigned deals. Now let me explain the anticipated phasing for this year. We expect total revenue and adjusted EBITDA to be higher in the second half, due to ramp-up new products and normal product seasonality. Specifically, we expect Q1 to be the lowest quarter for total revenue and adjusted EBITDA. We estimate free cash flow will be evenly weighted between the first half and second half. In general, Q2 and Q4 tend to be lower due to the timing of semiannual interest payments. It is important to note, in the revenue guidance walk on slide 33, the 2022 adjusted number of $15.65 billion excludes the 11-month biosimilar revenue included in our reported results. On a comparable basis, at the midpoint of revenue guidance, we expect total revenue of the underlying business to grow in 2023. Based on January FX rates, the full year guidance assumes minimal foreign exchange impact on total revenue, adjusted EBITDA, and free cash flow. We remain encouraged by the operational performance of our segment, the stability in global brands, and the expectation of approximately $500 million in new launches. In addition, we expect $56 million in revenue from Tyrvaya, our new eye care product. On Slide 34 are a few items that will impact adjusted EBITDA. First, we expect adjusted gross margin to be impacted by continued competition on key products. Next, adjusted gross margin of new products is expected to be above the company average. Third, we're investing in the Eye Care division, which includes commercial infrastructure and DTC investments in the second half of the year. We're making further investments to advance the deep Phase 3 ready eye care pipeline. Lastly, the other bucket includes the impact of continued inflation and investment with some offsetting benefits, including synergies. Turning to Slide 35. We expect another strong year of free cash flow generation as a result of expected lower one-time cash costs and continued focus on cash optimization initiatives. On Slide 36, I will now turn to our financial commitment, including return of capital to shareholders. To start, we have completed $250 million of share buyback under the previously announced $1 billion repurchase authorization. In addition, we anticipate an annual dividend of $0.48 per share. Taken together, this will increase our capital return by over 40% versus 2022. This represents a minimum payout of approximately 33% of the midpoint of free cash flow guidance. In addition to capital return, we will continue to prioritize debt reduction and expect to pay down our scheduled maturity of $1.3 billion in 2023, and thereby, we expect to deliver on our commitment of $6.5 billion of debt paydown in Phase 1. This is irrespective of proceeds from the divestiture. This demonstrates continued evidence of progress towards our stated gross leverage target of three times. With an extraordinarily strong financial position and benefiting from our investment-grade rating in this rising interest rate environment, with nearly all of our capital structure being fixed rate, we expect interest expense for 2023 to be flat versus 2022. In closing, we are well positioned for a strong start in 2023, which we consider our bridge year. The reshaping initiative will serve to strengthen the company and set us up well heading into 2024 and beyond. With that, I will hand it back to the operator to begin Q&As.

Thank you. At this time, we will open the floor for questions. We'll take our first question from Chris Schott with JPMorgan.

Great. Thanks so much for the question. Maybe just a bigger picture one to start out. I'm just trying to get my hands maybe a question for Robert and Scott. Just trying to understand the timing of the CEO transition here a bit more, I guess, it seems like you laid out a strategy kind of last fall. It seems like we're in the midst of kind of a divestiture repositioning of the company right now. So can you just talk a little bit about kind of why now on the transition versus either before we went down this process or a little bit later in the process? And if I just got a second clarification on the 2024 free cash flow number, I know you're not giving formal guidance, but that $2.3 billion of free cash flow, just so we are all on the same page, can you just elaborate on what's included in that number as we think about whatever you can say on EBITDA versus one-time costs, what you have for divestitures, etc.? I think just trying to make sure we're in the right adjustments to the $2.3 billion. Thanks so much.

First, I want to clarify that we are not repositioning the company. The focus of today's news is on preparation rather than change. From the beginning, we established a two-phase process. Phase 1 was centered on integration, synergy, and effectively merging the two organizations. We believed that having Michael lead the Upjohn division along with Sanjeev in their respective roles was the right choice for Phase 1. This has proven to be the perfect decision because the organization has been stabilized, integrated, and our synergies are on track. On November 7, we outlined a clear strategy for Phase 2. Once we defined that vision and strategy and created an execution plan, the final step was identifying the right leader with the appropriate background to support the strategy moving forward. Thus, this transition from Michael to Scott is a natural and authentic progression, considering both their backgrounds. You should not expect this to be a repositioning or a change in strategy. In fact, Scott has mentioned this in his prepared remarks. Scott, feel free to share your thoughts on this.

Yes, I want to thank you for the question, Chris, and I want to be very, very clear, I fully support the strategy that's been laid out, including the capital allocation strategy. On the November 7 strategic reset, certainly caught my attention. And then being on the Board since late 2022, I've had a chance to really deeply understand the strategy and where it's going, and I fully support it. The strategy and the way it's laid out is part of what made this opportunity very attractive to me. And I'm here to work with the team to execute it, not to deviate from it.

Yes, so sure. Chris, so nothing has changed from November 7. Chris, when we talked about that, including the fact that we provided an outlook of $2.3 billion on free cash flow for 2024. Chris, you've seen, we've demonstrated the last two years a very strong cash flow generation in the company. The entire focus on that, and that's allowed us to meet our Phase 1 commitment thus far. And that momentum will continue from that. So what's included in $2.3 billion are essentially a couple of things. First is we've considered all the divested business out of that number from $2.3 billion. What it does not include any divestment costs and any taxes on the divestment proceeds, which will actually be funded out of for the proceeds. So that's the number. That takes into account all the divestment, and we feel very confident about where we are. The guidance that we've given today, Chris, has a line of sight to all the moving pieces, and we remain very confident about the $2.3 billion outlook in 2024.

Yes. I would like to emphasize that we mentioned the projection of at least $2.3 billion for 2024, considering everything that Sanjeev explained. We are very confident that we will be able to manage even the one-time costs. While we're not providing specific guidance, we believe this metric is very important. Hopefully, we can absorb those one-time costs. The new information we shared today, despite not offering guidance for 2024, includes the growth we are seeing in our 2023 top line compared to 2022, excluding the biosimilars business. We're also observing accelerated top-line growth from 2023 to 2024. In our last call, when Umer asked about EBITDA conversion for cash flow and how it relates to EBITDA, I indicated a range of 4.6 to 5, and that estimate remains unchanged.

Hi, guys. Good morning. Thanks for taking my question. Hey Robert, I just wanted to follow up on these non-core divestitures. I mean, you all said a number of times that everything sort of remains on track. I was just wondering if you could sort of comment on the tone of those negotiations? And are you still comfortable with the level of proceeds from these transactions that you discussed historically, because you threw out some pretty high valuation multiples on those sales? And then, I guess, just a follow-up to that would be assuming you are, I mean, that's a lot of cash coming in the door. I was wondering if you could just sort of revisit some of your capital allocation priorities. I mean, you gave in the slide deck your capital allocation framework for the free cash flow, but that's a lot more money, and I'm trying to think about how you may want to deploy that vis-à-vis business development versus pay down versus repurchases?

Thank you, Glenn, that was insightful. Let me start from the beginning. If you could read my body language but not hear my voice, you'd see that we don't need to divest to achieve our Phase 1 targets. As Sanjeev mentioned, we will use operating cash flows, particularly to reduce our debt by at least $6.5 billion. We initially don't need to pursue divestitures, but we are doing so as part of our longer-term strategy and vision for the company's future. That's the best way to approach divestitures or negotiations. I believe that potential acquirers are aware of this, and I am pleased with our current position, especially in the OTC business, which I consider significant. We have a strong process in place that will progress naturally. We are confident that we will announce all three initiatives within this calendar year, and once the announcements are made, the timing of when proceeds arrive is less important. Regarding capital allocation, we will prioritize paying down debt to achieve our target leverage ratio of 3.0, as promised to the rating agencies. Any excess cash will be directed towards other investments. We remain committed to returning 50% of capital to shareholders through dividends and stock repurchases. Given our current stock price and the value we believe we have created, we view stock buybacks as a top investment opportunity for the company. Additionally, I believe the Oyster Point framework should be considered for the excess cash that will be deployed into the business after fulfilling our capital return commitments.

Hi. Good morning, and thanks for the question. A couple of ones – a couple of questions from me. Firstly, there's a fair bit of detail in the pipeline, excited to see that amongst the most proximate opportunities, I want to focus on to Glatiramer and also Tyrvaya launch. So with Glatiramer, we met with a partner recently, they expect around 5,000 patients to be prescribed in the first day of launch, and then expect to reach around 20,000 to 40,000 patients per year. I would like to get your confidence level on these expectations and what would the revenue trajectory look like? Secondly, on Tyrvaya, could you also please help us understand your peak expectations? And the EBITDA spend that you expect this year, a bigger part in the spend, what percent of this is recurring and what is one-off spend in 2023? Thank you.

We will provide confirmation about the trajectory and the patients in due time. I believe this will be a significant product for us starting in 2024 and 2025. What excites me more is the science behind it and the data we have analyzed. The perception may be that it is merely a convenient option, but it actually involves one injection compared to 12 injections, which is the current therapy, with 40 milligrams versus 480. More importantly, we have observed insights and data showing significant statistical results in the standard disability score, the EDSS, which directly relates to quality of life. This is where our excitement lies, as we will be able to include this in the label, driving its appeal. Additionally, it's important to note that this platform could potentially be used for numerous other opportunities in the future, such as the Glatiramer Acetate.

Yes. Good morning. This is Jeff Nau. And I want to give you an update on the question about Tyrvaya. In 2023, we expect that we will more than double revenue for Tyrvaya. There are a number of key fundamental drivers behind that number. The first being Medicare Part D coverage, which we did have – very minimal last year, we've grown that to almost 32.5% already. We expect that to continue to grow this year. We've also launched a 90-day script program, and we're investing in the business. And so we're really excited about investing in that from a marketing perspective. And so we expect to have a great year this year.

And Balaji, regarding the point about the investment, we saw that in the bridge that we provided on the IT division, SG&A investment, that's a function of investment in our field force, investment in the marketing program, and the investment in direct to consumer that we'll be implementing later in this year.

And investment in science.

And investment in science, in the R&D, yeah absolutely.

Hey, guys. Thanks for taking my questions. Just looking at the product level disclosure. So Lipitor and Norvasc have held up pretty nicely. I think it was about $2.4 billion in revenue. So it looks like those products have weathered the VBP process. And I'm just trying to get a sense, if you can speak to the extent to which sales of these products are still concentrated in China. And really trying to frame product concentration risk, it would seem like these two products probably contribute a pretty substantial amount of EBITDA by our estimate, maybe even close to $2 billion. So just wanted to get any framing that you can offer there? And then just on sort of the 2028 outlook for the $1 billion in additional revenue, is there any specific Famy product that you'd say is the biggest contributor to that? Thanks.

Let me discuss China and the products Lipitor and Norvasc. One of the key factors for their stability is the effective management of these established brands. We've observed consistent growth of around 1% to 2% for Lipitor, Norvasc, and Xanax in both emerging markets and Europe. In China, our business remains solid despite the challenges posed by COVID lockdowns, demonstrating strength in our operations. We have a skilled team and a strong commercial infrastructure in China that understand the local nuances and the rationale behind government policies, which we fully support as they aim to expand sales. Our business has adapted to cover two segments: public reimbursement and private pay channels. We have adjusted our approach to capture patients transitioning from public reimbursement to private pay. From a modeling perspective, we anticipate a slightly flat or small decline, but overall, the business is performing very well.

And then I'll touch base on the eye care portfolio and pipeline. I think what's important here is these numbers that we've shared are really risk-adjusted. When you look at the entire portfolio, we see that of that $1 billion target, about 60% will come globally from dry eye disease assets, about two-thirds of those from the US and about one-third of those from the rest of the world. Approximately 20% will come from Blepharitis globally and approximately 20% will come from all other assets in the pipeline. But as you can see, we have a robust pipeline with a number of different indications with significant unmet needs.

And if I can just add, just to highlight, Blepharitis, Presbyopia, and Reversal of Mydriasis, these are some unmet need or there is no prescribed established therapy. So that's why these products fit in very nicely over there.

Thank you. Good morning. I have a question for Rajiv. Regarding the expectations for new product launches in 2023, it seems that the actual performance in 2022 did not exceed expectations. Could you provide some insights into the 2022 performance, specifically whether the revenue from new products fell short of expectations due to the performance of the assets or if it was primarily related to the timing of approvals? Additionally, what factors might enhance our confidence in your expectations for 2023? Considering some of the anticipated approvals, such as Iron Sucrose, which has gone through several iterations at the FDA, I am curious about its potential contribution. Could you highlight one or two aspects that would strengthen your outlook for new products in 2023? Thank you.

Yeah, let me first answer your 2022 question. And it was not underperforming of the approved assets. It was more from some delay. If you recall, 2022 included a couple of biosimilars where we were waiting for the first approval of Aspart, biosimilar to Aspart and biosimilar to Avastin. That didn't happen because of the issues with the Biocon facility. So that was the primary reason behind that miss. But going into 2023, as we have always said to you, we're not dependent upon one product over here. Every product is risk-adjusted; products like Symbicort and we still have the trailing effect of the products like lenalidomide this year. But yes, iron sucrose, it is a complex product you will appreciate. And when you are trying to bring a first to the market, there can be sometimes more iterations. But we are at a point with a science where we see it happening. And all those factors have been considered to build this 2023 number. And I feel very confident at the beginning of the year that this number, as I said, put out that 98% of these products are either approved or already launched or a couple of products are pending approval, that's where the iron sucrose comes in.

Hi. Thanks for taking my question. So I have two on capital allocation real quick. So what drove the decision to keep the dividend per share flat this year? I know, last year, we saw a 9% growth. And then on share repurchases, any change in thinking on the timing here in the light of President Biden calling for a quadrupling of tax on buybacks? Thanks.

Hi, Ash. I believe that the key focus for us is total shareholder return, which is fundamentally based on both dividends and share buybacks. From the beginning, we committed to establishing a baseline for our dividend, which we deemed important to fulfill. However, given the current trading levels of our stock, it is clear that the best way to utilize any excess capital is by repurchasing our own shares. That's what you can expect from us moving forward. Until we see stock levels that more accurately reflect our valuation, we will continue to buy back shares. I strongly encourage the investment community to remember that total shareholder return is a blend of dividends and share buybacks, as we stated from the start. As Sanjeev noted earlier, we have already returned 33% of our free cash flow and are considering an increase percentage as well.

At a minimum 40%.

And a return of 40% greater than we did all of 2022. And you guys should expect that going forward. Remember, as we go into 2024, I believe the company will be well positioned to convert from a valuation from this EBITDA, especially as we pay down our debt and get it to the three times to really convert it over to an adjusted earnings per share strategy. I see tremendous growth as an adjusted earnings per share because of our capital allocation commitment to the investment community of return at least 50% through the dividend and more importantly, the share buyback.

Thanks. Good morning. First one for Scott. Do you think you might want to do anything differently in terms of positioning the company to be more successful on the branded side of the house, given your experience there? And I'm curious how you think about some of the planned initiatives to expand into areas like ophthalmology, GI, and derm, that's been talked about in the past? So what do you hope to leverage on the branded side in terms of your experience? And then for the team, just in North America, with the guidance down 3% this year, just at what point do you think the new product revenue will be able to offset that base erosion and return to growth in North America? Is that something that can happen next year based on the trajectory that you're seeing? And maybe talk about if you're still comfortable maintaining that same level of base erosion now going forward? Thank you.

Why don't you take this backwards? Why don't you go first and then let's Scott close. Yes, I believe I have provided clarity. Overall, from a stability perspective, I am confident that this is sustainable stability, and we are actually observing acceleration in top line growth. While we are not providing guidance, we anticipate that this enhanced stability will lead to positive outcomes. Focusing on North America, there are no significant losses to report. I consider the market and performance to be the challenges for our North American business. We do not foresee any major allowances. Looking ahead to 2024, your expectations are valid; you should expect North America to return to growth, with any basic erosion being countered by new product launches in the region.

So Gary, thank you very much for the question. I think a very important part of the strategy is moving up the value chain as we move into Part II and beyond. I think the eye care transactions that happened recently are a very good model for the way that we're going to want to do BD going forward. You mentioned the therapeutic areas of interest, obviously, through my branded experience with Otezla and others, I'm very familiar with the GI space and with, of course, the derm space. These are two areas that I think fit our strategy very, very well. But I will say, I think I want to be a little bit opportunistic as well. If there are opportunities outside of these tidy areas that fit our model going forward, we should be very open-minded to engage in those as well. So this, to me, is a very, very important and exciting part of the strategy, moving up the value chain, and I'm really excited to be leading that effort.

Thank you. I would like to explore your long-term expectations regarding complex products and brands. You mentioned that novel and complex products could reach peak sales of about $1 billion by 2028. I understand you discussed glatiramer administered once a month, but I'm curious about other standout products, such as the meloxicam product for post-surgery, which was recently discontinued. What makes you see that as a significant opportunity? Also, on the brand side related to eye care, you mentioned it primarily involves dry eye. Can you clarify if that includes Tyrvaya or other products? I’d appreciate more details on the product mix. Thank you.

Okay. Let me just start. And I think I'd rather you not speak about any one particular product, but the franchises that we outlined on November 7th. So the ophthalmics being one, the complex generics being another. Rajiv, why don't you outline each of the franchises, and then let's articulate a little bit about what's inside those franchises?

We discussed in detail three main categories of billion-dollar franchises. The first is eye care, which is the most recent addition. The second is complex injectables, and the third includes complex products. In the realm of complex injectables, nearly ten products are currently under FDA review, with seven having secured first market positions. Additionally, we anticipate three to four products will be submitted for filing in 2023. We have around 33 products in development. Following Effexor's model, we also consider complex 505(b)(2) products like Botox and Xulane Low Dose. Importantly, meloxicam is progressing well; we have recently completed Phase IIb and have an end-of-Phase II meeting with the FDA scheduled in the coming months. This product is set to advance to Phase III clinical studies later this year. There's significant activity in this area, as Botox, Xulane Low Dose, Effexor, and meloxicam are all entering Phase III later this year.

Yes. And David, I would just say when you look at the franchises and you look at their makeup and the word complexity should also telegraph how much competition we anticipate at market formation and also the type of pricing that we anticipate as well.

And also, let's not underestimate the pipeline, which is markets like China, Japan, and Europe separately because to offset their basic erosion. That pipeline never existed. That pipeline has been created. So that pipeline will be also coming into play.

Tyrvaya for…

And so when we talk about the eye care franchise and dry eye, in particular, I think one of the things that's really important to appreciate what the pipeline is Tyrvaya really has a very unique mechanism of action. It's the only product out there that stimulates the production of natural tear film. When you think about dry eye disease, it's a multifactorial disease. So we won't stop understanding how to treat this disease just because we're launched Tyrvaya and we're selling Tyrvaya. There may be other mechanisms that can be added in there. And that's the nice part about Tyrvaya’s. It really is a product that stands by itself and is able to be used with any other dry eye product that's out there in the market. The other thing that I think is really important is we haven't really scratched the surface outside of the US, and that's really an important market to go into and with the power of Viatris and all the supply chain and the ability to grow outside the US, I think that's something that we look forward to as well.

Hi, everyone. Thank you for taking my question. I have two questions, both for Robert. Robert, I'm struggling to understand why Michael is leaving, and I'm interested in your perspective on this, particularly in light of the divestitures that Viatris is undertaking, as the Upjohn segment of the business is only becoming larger. The timing of this departure also seems unexpected, and I think many are quite confused about it. My second question is regarding Ian Read, who also left in December. Are these two departures related, or not? It's hard not to consider them together.

Well, Umer, you can choose to see the situation negatively or positively. I appreciate your question and the chance to discuss it. Honestly, we are only partially through our process, and there's still more to come. Let's start with Ian Read. You should know that Ian was on the Board and was very supportive of Scott Smith. Ian was part of the decision to bring Scott on board and provided us with valuable advice and support. He understands the strategy and has contributed significantly during his time with us. I regret that he decided to step down as he has other commitments, but his departure was for the right reasons. I am grateful for Ian’s support in helping us with Scott. Ian has a long history with Scott's previous boss, and that insight was incredibly valuable to the Board. Regarding our business life cycle, most companies undergo changes when they encounter problems. However, we have been clear about our goals for Phase I. I previously stated that Michael was the right person to unify the organizations, considering he and Sanjeev managed the Upjohn division and its product portfolio. Now that we are looking ahead to Phase II, I believe I've been clear about our vision since November 7. Our strategy and execution plan are in place, and we are looking for the right leader. Scott's background aligns perfectly with this task, and his extensive experience and construction-oriented mindset are exactly what we need. Changes in companies shouldn’t automatically be associated with negative reasons. I believe you can hear this positivity in Michael's voice. The upcoming months are crucial for transitioning to Phase II, and it provides a valuable opportunity for any new leader to prepare before we reach 2024 and beyond. That’s all there is to it, Umer. I'm happy to answer any follow-up questions you may have.

Good morning, folks. Thanks for taking the questions. For the $500 million of new product revenue that you expect this year, what are the most important two to three contributors to that number? And just a quick follow-up on Glatiramer, the once monthly program, how much sales do you generate with your generic Copaxone? And how are you thinking about the potential impact of the once monthly product on your generic sales? Thanks so much.

On the Copaxone, you can pick up the IMS data where we have about 51% market share. We have slowly built it over the last three to four years. Today, we have about more than what Tyrvaya had in that market, and it's been a meaningful product for several years. And Copaxone once a month will be a very meaningful product as we launch this product later in the second half of 2024 and beyond that. And $500 million, as I always said, we never built it on sort of this pipeline of $500 million. It's not on one product. So there's a tailing effect of lenalidomide in this, of course, but then there are products like Symbicort, which we have been very publicly telling you where we are, and that is a risk-adjusted basis. We are looking forward to launch these products in 2023. So there are many more products like that.

Thank you. This concludes today's Viatris 2022 fourth quarter and 2023 guidance call and webcast. Please disconnect your line at this time and have a wonderful day.